Premium
Identification of annexin II as a novel secretory biomarker for breast cancer
Author(s) -
Jeon You Rim,
Kim Sun Young,
Lee Eun Jeong,
Kim Yong Nyun,
Noh DongYoung,
Park So Yeon,
Moon Aree
Publication year - 2013
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201300127
Subject(s) - breast cancer , annexin a2 , annexin , cancer research , biomarker , cancer , annexin a1 , cancer cell , filopodia , annexin a5 , motility , metastasis , biology , actin cytoskeleton , medicine , pathology , cell , immunology , cytoskeleton , microbiology and biotechnology , flow cytometry , biochemistry
Early prediction of metastatic breast cancer is important for improvement of prognosis and survival rate. The present study aimed to identify secreted protein biomarkers for detection of invasive breast cancer. To this end, we performed a comparative proteomic analysis by a combination of 2 DE and MALDI ‐ TOF MS analysis of conditioned media from invasive H ‐Ras MCF 10 A human breast epithelial cells and noninvasive MCF 10 A and N‐Ras MCF 10 A cells. We identified a list of 25 proteins that were strongly detected in media of H‐Ras MCF 10 A and focused on annexin II, which was shown to be involved in cell motility. Invasive triple‐negative human breast carcinoma cells, Hs578T, and MDA‐MB ‐231, showed increased levels of annexin II in media, demonstrating that secretion of annexin II correlated well with the invasive phenotype of cells. We demonstrated a crucial role of annexin II in breast cell invasion/migration and actin cytoskeleton reorganization required for filopodia formation. Annexin II levels in the plasma samples and breast cancer tissues of breast cancer patients were significantly higher than those of normal groups, providing a clinical relevance to our in vitro findings. Taken together, we identified annexin II as a novel secretory biomarker candidate for invasive breast cancer, especially estrogen receptor‐negative breast cancer.